PE20212073A1 - Modificacion de un anticuerpo para la union selectiva al tumor de cd47 - Google Patents

Modificacion de un anticuerpo para la union selectiva al tumor de cd47

Info

Publication number
PE20212073A1
PE20212073A1 PE2021001666A PE2021001666A PE20212073A1 PE 20212073 A1 PE20212073 A1 PE 20212073A1 PE 2021001666 A PE2021001666 A PE 2021001666A PE 2021001666 A PE2021001666 A PE 2021001666A PE 20212073 A1 PE20212073 A1 PE 20212073A1
Authority
PE
Peru
Prior art keywords
binds
fab
tumor
antibody
modification
Prior art date
Application number
PE2021001666A
Other languages
English (en)
Inventor
Haralambos Hadjivassiliou
Dan Zhu
Jeonghoon Sun
Sharmistha Acharya
Jeffrey Johnson
Kandasamy Hariharan
Ho Cho
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PE20212073A1 publication Critical patent/PE20212073A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta referido a anticuerpos que comprenden al menos una parte de Fab que se une a CD47 y al menos una parte de Fab que se une al antigeno asociado al tumor (TAA) CD20; en donde la parte de Fab que se une a CD47 exhibe baja afinidad para CD47; y, en donde la parte de Fab que se une a CD20 exhibe alta afinidad para CD20; y en donde el anticuerpo se une de manera selectiva a CD47 y bloquea la interaccion de CD47 con SIRPalfa en celulas tumorales a la vez que no exhibe una union sustancial a CD47 en celulas normales. Estos anticuerpos se emplean en el tratamiento de neoplasias malignas hematologicas o de trastornos de linfocitos B en un paciente
PE2021001666A 2019-04-05 2020-04-03 Modificacion de un anticuerpo para la union selectiva al tumor de cd47 PE20212073A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830335P 2019-04-05 2019-04-05
PCT/US2020/026579 WO2020206255A1 (en) 2019-04-05 2020-04-03 Engineering of an antibody for tumor-selective binding of cd47

Publications (1)

Publication Number Publication Date
PE20212073A1 true PE20212073A1 (es) 2021-10-26

Family

ID=70457134

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001666A PE20212073A1 (es) 2019-04-05 2020-04-03 Modificacion de un anticuerpo para la union selectiva al tumor de cd47

Country Status (18)

Country Link
US (2) US20220162330A1 (es)
EP (2) EP3946633A1 (es)
JP (2) JP2022535324A (es)
KR (2) KR20210148290A (es)
CN (2) CN114667168A (es)
AR (2) AR118595A1 (es)
AU (1) AU2020252402A1 (es)
BR (1) BR112021019714A2 (es)
CA (1) CA3134964A1 (es)
CL (1) CL2021002608A1 (es)
CO (1) CO2021013836A2 (es)
EA (1) EA202192729A1 (es)
IL (1) IL286889A (es)
MX (1) MX2021012178A (es)
PE (1) PE20212073A1 (es)
SG (1) SG11202110736VA (es)
TW (2) TW202104260A (es)
WO (2) WO2020206255A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4376884A1 (en) * 2021-07-30 2024-06-05 Ludwig-Maximilians-Universität München Anti-cd47 antibodies and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE13746964T2 (hu) 2012-02-06 2020-01-28 Inhibrx Inc CD47 antitestek és alkalmazási eljárásaik
ES2773107T3 (es) * 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
ES2876009T3 (es) * 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
EP4137518A1 (en) * 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US20160009824A1 (en) * 2013-03-15 2016-01-14 Merck Patent Gmbh Tetravalent bispecific antibodies
US10087257B2 (en) * 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
ES2751915T5 (es) * 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
CN114716552B (zh) * 2016-01-11 2024-05-24 四十七公司 人源化、小鼠或嵌合抗cd47单克隆抗体
US11427632B2 (en) 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof
EP3586872A4 (en) * 2017-02-24 2020-12-30 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION, ANTIG-BINDING MOLECULES, TREATMENT METHODS AND SCREENING METHODS
US20200330590A1 (en) 2017-03-27 2020-10-22 Celgene Corporation Methods and compositions for reduction of immunogenicity
US11518810B2 (en) * 2017-05-08 2022-12-06 Shanghai Jmt-Bio Technology Co., Ltd. Bispecific recombinant protein and use thereof

Also Published As

Publication number Publication date
SG11202110736VA (en) 2021-10-28
CL2021002608A1 (es) 2022-06-10
EP3946633A1 (en) 2022-02-09
WO2020206255A1 (en) 2020-10-08
MX2021012178A (es) 2021-11-04
JP2022528869A (ja) 2022-06-16
EA202192729A1 (ru) 2022-01-13
WO2020206251A1 (en) 2020-10-08
IL286889A (en) 2021-10-31
EP3946634A1 (en) 2022-02-09
US20220340675A1 (en) 2022-10-27
AU2020252402A1 (en) 2021-11-18
KR20210148317A (ko) 2021-12-07
CN114667168A (zh) 2022-06-24
CN114269435A (zh) 2022-04-01
KR20210148290A (ko) 2021-12-07
TW202045550A (zh) 2020-12-16
US20220162330A1 (en) 2022-05-26
AR118595A1 (es) 2021-10-20
BR112021019714A2 (pt) 2021-12-14
TW202104260A (zh) 2021-02-01
CA3134964A1 (en) 2020-10-08
CO2021013836A2 (es) 2022-03-29
AR118594A1 (es) 2021-10-20
JP2022535324A (ja) 2022-08-08

Similar Documents

Publication Publication Date Title
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CU20200090A7 (es) Anticuerpos frente a entpd2 y terapias de combinación
EA202190542A1 (ru) Сконструированные биспецифические белки
CL2010000788A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
MX2021004588A (es) Anticuerpo anti-cldn18.2 y sus usos.
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
AR041650A1 (es) Anticuerpos que se unen a polipeptidos ca125/o772p cuando estos se encuentran asociados a las celulas. metodos relacionados
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
MX2022007636A (es) Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
PE20230381A1 (es) Proteina de union a rgma
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
CR20220660A (es) Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
PE20212073A1 (es) Modificacion de un anticuerpo para la union selectiva al tumor de cd47
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma
BR112018006820A2 (pt) anticorpos anti-psa (5a10) humanizados